PT-141 / Bremelanotide

At a Glance

Mechanism of Action

Bremelanotide (PT-141) is a cyclic heptapeptide derived from the melanocortin analog Melanotan II (MT-II). It is a nonselective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, with its therapeutic effects on sexual function primarily attributed to activation of MC3R and MC4R in the central nervous system.[1][2]

The mechanism of action for sexual desire enhancement is fundamentally different from PDE5 inhibitors (sildenafil, tadalafil) and other peripheral vasodilatory agents:

• Central mechanism: PT-141 acts on MC3R and MC4R in the hypothalamus, medial preoptic area, and other CNS nuclei that regulate sexual arousal, desire, and motivation. This central action means it modulates the desire/arousal pathway upstream of peripheral genital response.[2]
• MC4R activation: The MC4R is expressed in hypothalamic paraventricular nuclei and is a key regulator of sexual behavior. MC4R activation stimulates downstream oxytocin and dopaminergic signaling pathways involved in sexual arousal.[3]
• MC3R activation: MC3R contributes to the modulation of sexual motivation and reward circuits. The relative contribution of MC3R versus MC4R to the clinical effect is still being elucidated.[4]
• Not a vasodilator: Unlike PDE5 inhibitors, PT-141 does not directly increase genital blood flow. Its pro-sexual effects are mediated centrally, making it effective for desire-phase disorders rather than purely mechanical arousal or erectile function.[1]

Clinical Evidence

RECONNECT Trials (Phase 3)

The FDA approval of Vyleesi was based on two identical Phase 3, randomized, double-blind, placebo-controlled trials (RECONNECT 1 and RECONNECT 2) conducted in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).[6]

• Population: 1,247 premenopausal women with HSDD (combined enrollment across both trials)
• Design: 24-week, at-home, as-needed subcutaneous self-administration of 1.75 mg bremelanotide or placebo
• Primary endpoints: Change from baseline in the Female Sexual Function Index-desire domain (FSFI-D) score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 (distress related to low sexual desire)

Results showed statistically significant improvements in both co-primary endpoints compared to placebo:[6][7]

Earlier Clinical Studies

• Diamond et al. (2006): Phase 2 study of intranasal bremelanotide in premenopausal women with female sexual arousal disorder (FSAD). Demonstrated significant increases in genital arousal and subjective desire compared to placebo. The intranasal route was later abandoned due to blood pressure concerns.[9]
• Pfaus et al. (2004, 2007): Preclinical studies in female rat models demonstrating that melanocortin agonists stimulate solicitation behavior and lordosis, supporting a CNS-mediated mechanism of action for sexual arousal.[10]
• Rosen et al. (2015): Phase 2b dose-ranging study (n=327) that established the 1.75 mg subcutaneous dose as optimal, balancing efficacy with tolerability (primarily nausea).[11]

Male Erectile Dysfunction Studies

Early Phase 2 studies evaluated PT-141 in men with erectile dysfunction (ED). Diamond et al. (2004) reported that intranasal PT-141 produced erections in men with ED, including some who had failed sildenafil. However, the male ED indication was not pursued to Phase 3 due to the blood pressure effects observed with the intranasal route and subsequent regulatory focus on the female HSDD indication.[12]

Primary Uses

FDA-Approved Indication

• Hypoactive sexual desire disorder (HSDD) in premenopausal women: Vyleesi is approved for the treatment of acquired, generalized HSDD in premenopausal women, as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not attributable to a coexisting medical or psychiatric condition, relationship problems, or medication/substance effects. Approved June 2019.[13]

Off-Label / Investigational Uses

• Male erectile dysfunction: Not FDA-approved for this indication. Early clinical data showed promise but the indication was not pursued through Phase 3.[12]
• Male sexual desire: Anecdotal and early-phase clinical evidence suggests pro-sexual effects in men; no controlled Phase 3 data.
• Post-menopausal HSDD: Not studied in Phase 3 trials in post-menopausal women; efficacy in this population is unknown.

Contraindications

• Uncontrolled hypertension or cardiovascular disease: PT-141 causes a transient increase in systolic and diastolic blood pressure (mean ~3 mmHg systolic, ~2 mmHg diastolic) and a transient decrease in heart rate following each dose. In patients with uncontrolled hypertension or known cardiovascular disease, this hemodynamic effect poses an unacceptable risk. Blood pressure should be controlled prior to initiation.[13]
• Pregnancy: Bremelanotide is contraindicated in pregnancy. Melanocortin signaling plays a role in fetal development; animal studies showed adverse developmental effects. A pregnancy test should be performed before prescribing.[13]
• Known hypersensitivity: History of serious hypersensitivity reaction to bremelanotide or any component of the formulation.[13]

Relative Contraindications / Precautions

• Patients on antihypertensive medications: Additive blood pressure effects may occur; monitor blood pressure during initial use.
• Patients on naltrexone: Concomitant use reduces the efficacy of bremelanotide (see Drug Interactions).
• History of melanoma or dark, atypical nevi: MC1R activation may theoretically promote melanocyte proliferation. While no causal link to melanoma has been established, caution is warranted in high-risk individuals.
• Hepatic impairment: Not studied in patients with severe hepatic impairment; use with caution.
• Renal impairment: Not studied in patients with eGFR <30 mL/min; use with caution.

Standard Protocols

FDA-Approved Dosing (Vyleesi)

Administration

1. Remove the autoinjector from the refrigerator and allow it to reach room temperature (approximately 30 minutes)
2. Clean the injection site on the abdomen or thigh with an alcohol swab
3. Remove the pen cap and press the autoinjector firmly against the skin
4. Press the injection button and hold for 5 seconds
5. Dispose of the used autoinjector in a sharps container

Stacks & Combinations

PT-141 is typically used as monotherapy for HSDD. Potential co-administration scenarios include:

• With PDE5 inhibitors (sildenafil, tadalafil): Mechanistically complementary — PT-141 acts centrally on desire while PDE5 inhibitors act peripherally on arousal/erection. Some clinicians report combination use in men, though no controlled data exist for this combination and blood pressure monitoring is recommended.
• With testosterone replacement: In women with HSDD, low-dose testosterone may be used adjunctively. The interaction between melanocortin agonism and androgen-mediated desire pathways has not been formally studied.
• With flibanserin (Addyi): Both target HSDD through different CNS pathways (melanocortin vs. serotonergic). Combination use has not been studied and is not recommended without clinical guidance.

Preparation & Administration

Commercial Formulation (Vyleesi)

Vyleesi is supplied as a single-dose, prefilled, disposable subcutaneous autoinjector containing 1.75 mg bremelanotide in 0.3 mL solution. No reconstitution or dose calculation is required.

Compounded / Research Formulations

Research chemical versions of PT-141 (bremelanotide acetate) are available as lyophilized powder, typically in 10 mg vials. Reconstitution is required for these formulations:

Injection Technique (Compounded)

• Use a 29–31 gauge, 0.5-inch insulin syringe
• Inject subcutaneously into the abdomen or thigh
• Rotate injection sites to minimize skin reactions
• Administer at least 45 minutes before anticipated activity

Side Effects

Common Adverse Reactions

Cardiovascular Effects

• Transient hypertension: Mean increases of ~3 mmHg systolic and ~2 mmHg diastolic blood pressure, peaking 2–3 hours after injection and resolving within 12 hours.[13]
• Transient heart rate decrease: Small reductions in heart rate have been observed post-dose.[13]

Other Notable Effects

• Hyperpigmentation: Focal darkening of the skin, particularly the face, gingiva, and breasts, has been reported with repeated use. This is related to MC1R agonism stimulating melanogenesis. Hyperpigmentation may be persistent or slow to resolve after discontinuation.[13]
• Injection site reactions: Bruising, erythema, and pruritus at the injection site. Typically mild and self-limiting.

Drug Interactions

Storage

• Vyleesi autoinjectors: Refrigerate at 2–8°C (36–46°F). May be stored at room temperature (up to 30°C / 86°F) for up to 30 days. Do not return to refrigerator once stored at room temperature.
• Do not freeze. Discard if frozen.
• Protect from light. Store in the original carton.
• Compounded vials (reconstituted): Refrigerate at 2–8°C. Use within 30 days of reconstitution with bacteriostatic water.

Legal Status

• United States: FDA-approved prescription medication. Vyleesi (bremelanotide) was approved June 21, 2019 for HSDD in premenopausal women. Schedule: Rx only (not a controlled substance).[13]
• Approved indication is narrow: Only approved for premenopausal women with acquired, generalized HSDD. Not approved for men, post-menopausal women, or generalized sexual enhancement.
• Research chemical versions: PT-141 / bremelanotide acetate is available from research chemical suppliers. These products are sold for research purposes only and are not FDA-approved pharmaceutical products.
• Compounding: Some compounding pharmacies produce bremelanotide for clinical use under physician prescription.
• International: Not approved in the EU or most other jurisdictions as of April 2026.
• WADA: Not on the 2026 WADA Prohibited List.

Open Questions

• Efficacy in males: Phase 2 data suggested PT-141 could treat erectile dysfunction through a central mechanism, potentially effective even in PDE5 inhibitor non-responders. No Phase 3 male ED trial has been completed. Whether a commercial development program for the male indication will be pursued remains uncertain.[12]
• Long-term hyperpigmentation risk: The extent, reversibility, and clinical significance of MC1R-mediated hyperpigmentation with chronic use (beyond 24 weeks) is not well-characterized. Whether this has any relationship to melanocyte dysplasia or melanoma risk is unknown.
• Optimal PRN timing: The prescribing information recommends administration at least 45 minutes before anticipated activity. The optimal timing window and peak subjective effect have not been precisely defined. Patient-reported optimal timing may vary.
• Post-menopausal efficacy: HSDD is prevalent in post-menopausal women, yet Phase 3 trials were restricted to premenopausal women. Whether the melanocortin pathway responds similarly in the post-menopausal hormonal milieu requires dedicated study.
• Nausea mitigation strategies: Whether pre-treatment with antiemetics (ondansetron, etc.) can reduce the 40% nausea rate without compromising efficacy has not been formally studied.
• Combination with flibanserin: Both target HSDD through distinct CNS mechanisms. Whether combination therapy provides additive benefit is unexplored.
• Cardiovascular long-term safety: The transient BP elevation with each dose has been characterized in short-term studies, but long-term cardiovascular consequences of repeated use in hypertension-prone populations are unknown.

Bibliography

1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x · PubMed 12851303
2. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-10204. doi:10.1073/pnas.0400491101 · PubMed 15226502
3. Van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A. 2002;99(17):11381-11386. doi:10.1073/pnas.172378699 · PubMed 12172010
4. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. doi:10.1016/S0022-5347(01)62911-2 · PubMed 9679884
5. Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689. doi:10.1016/j.peptides.2005.01.023 · PubMed 15996790
6. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500 · PubMed 31599840
7. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. doi:10.2217/whe-2016-0018 · PubMed 27181684
8. Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453-462. doi:10.1001/jamainternmed.2015.8565 · PubMed 26927498
9. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. doi:10.1111/j.1743-6109.2006.00268.x · PubMed 16839319
10. Pfaus JG, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4(Suppl 4):269-279. doi:10.1111/j.1743-6109.2007.00610.x · PubMed 17958622
11. Portman DJ, Edelson J, Jordan R, Clayton A, Krychman M. Bremelanotide for hypoactive sexual desire disorder: analyses from a phase 2b dose-ranging study. Obstet Gynecol. 2014;123(Suppl 1):31S. doi:10.1097/01.AOG.0000447162.65796.a5
12. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. doi:10.1038/sj.ijir.3901131 · PubMed 14963471
13. U.S. Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. Approved June 2019. FDA Label